ResearcherFoundation Medicine (United States)No recent work listed

Kuei‐Ting Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-7558-2447; OpenAlex author ID A5086972914. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2023: 1 paper

Papers 1

A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyad178 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jie He · 1 shared paper, 2023 · strength 0.15
- Paper A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer. DOI 10.1093/oncolo/oyad178 ↗
Ethan S. Sokol · 1 shared paper, 2023 · strength 0.15
- Paper A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer. DOI 10.1093/oncolo/oyad178 ↗
Michael Jon Pishvaian · 1 shared paper, 2023 · strength 0.15
- Paper A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer. DOI 10.1093/oncolo/oyad178 ↗
Aatur Dilip Singhi · 1 shared paper, 2023 · strength 0.15
- Paper A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer. DOI 10.1093/oncolo/oyad178 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.